MedTrace Logo

Clonal Emergence and Regression During Radium-223 Therapy for Metastatic Prostate Cancer

NCT03677076 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2024-01-17

No results posted yet for this study

Summary

This study is for patients with metastatic prostate cancer receiving radium-223 as their standard of care therapy. The researchers will collect blood and urine samples from patients before, during and after the radium-223 therapy. The researchers will compare these samples to observe how the treatment has affected different cancer markers.

Conditions

Interventions

OTHER

Ancillary/Correlative

Collection of research blood and urine

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Michael Lilly, MD · Medical University of South Carolina

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677076 on ClinicalTrials.gov